Quest Diagnostics
895 hedge funds and large institutions have $15B invested in Quest Diagnostics in 2024 Q4 according to their latest regulatory filings, with 124 funds opening new positions, 313 increasing their positions, 300 reducing their positions, and 59 closing their positions.
110% more first-time investments, than exits
New positions opened: 124 | Existing positions closed: 59
81% more call options, than puts
Call options by funds: $63.1M | Put options by funds: $35M
6% more funds holding
Funds holding: 846 → 895 (+49)
1.22% more ownership
Funds ownership: 87.82% → 89.04% (+1.2%)
4% more repeat investments, than reductions
Existing positions increased: 313 | Existing positions reduced: 300
1% less capital invested
Capital invested by funds: $15.2B → $15B (-$172M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$255M |
| 2 |
JP Morgan Chase
New York
|
+$143M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$91.5M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
+$77.5M |
| 5 |
Millennium Management
New York
|
+$76.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
American Century Companies
Kansas City,
Missouri
|
-$119M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$116M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$85.4M |
| 4 |
Goldman Sachs
New York
|
-$64.9M |
| 5 |
Invesco
Atlanta,
Georgia
|
-$44.1M |
DGX Hedge Fund Activity: Q4 2024 in Review
895 of the 7,592 institutional investors tracked by Wall St. Rank reported a position in Quest Diagnostics (DGX) for Q4 2024, worth a combined $15B — down 1.1% from $15.2B a quarter earlier.
Buyers outnumbered sellers: 124 funds opened new DGX positions and 59 closed out — a net gain of 65 holders — while 313 added to existing stakes and 300 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $255M. The largest seller was American Century Companies, cutting an estimated $119M.
- 895 institutional investors held Quest Diagnostics (DGX) as of Q4 2024, up from 846 in Q3 2024.
- Funds reported $15B of Quest Diagnostics stock for Q4 2024, down 1.1% quarter-over-quarter.
- 124 funds opened new Quest Diagnostics positions in Q4 2024 and 59 closed out, a net change of +65 holders.
- The largest Quest Diagnostics buyer in Q4 2024 was T. Rowe Price Associates, an estimated $255M added.
- The largest Quest Diagnostics seller in Q4 2024 was American Century Companies, an estimated $119M sold.
Based on aggregated 13F filings for Q4 2024.